| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | -363 | -292 |
| Proceeds from debt refinancing | 0 | 0 |
| Payment of debt discount | 0 | 0 |
| Proceeds from issuance of employee stock purchase plan shares | 830 | 830 |
| Proceeds from exercise of stock options | 10,994 | 5,833 |
| Proceeds from issuance of warrants | 9,167 | - |
| Repurchase of common stock withheld for taxes | 9,336 | 8,858 |
| Net cash provided by (used in) financing activities | 11,655 | -2,195 |
| Net cash provided by (used in) in cash, cash equivalents and restricted cash | 19,875 | -12,336 |
| Cash and cash equivalents at beginning of period | 75,744 | - |
| Cash and cash equivalents at end of period | 95,619 | - |
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)